Skip to search formSkip to main contentSkip to account menu

LY2510924

Known as: CXCR4 Peptide Antagonist LY2510924 
An inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity. Upon subcutaneous administration, CXCR4 inhibitor LY2510924… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Cyclic Peptides
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Elucidating the Molecular Biomarkers Associated with Increase Responsiveness to a Cyclic Peptide CXCR4 Antagonist, LY2510924, in an Orthotopic Xenograft Mice Model on Colorectal Cancer Tumor Growth…
2019
2019
EXAMINING THE EFFECT OF A CYCLIC PEPTIDE CXCR4 ANTAGONIST, LY2510924, IN AN ORTHOTOPIC XENOGRAFT MICE MODEL ON COLORECTAL CANCER TUMOR GROWTH AND METASTASIS
2018
2018
Evaluating the Inhibitory Effects of LY2510924, a Cyclic Peptide CXCR4 Antagonist, in Human Colon Cancer Metastasis Using an Orthotopic Xenograft Model
2018
2018
Initial report of a phase I study of LY2510924 with idarubicin and cytarabine (IA) in relapsed/refractory (R/R) AML.
7026Background: LY2510924 is a peptide antagonist of CXCR4, a key component of the CXCR4/SDF-1 signaling axis that is critical… 
2015
2015
Randomized phase II study of sunitinib + CXCR4 inhibitor LY2510924 versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.
4547 Background: Sunitinib is a standard first-line treatment for patients (pts) with metastatic renal cell carcinoma (RCC… 
2015
2015
Evaluation of CXCR4 expression on tumor and circulating tumor cells (CTCs) as predictive response marker for CXCR4 antagonist LY2510924 in combination with carboplatin-etoposide in extensive-disease…
7567 Background: Small cell lung cancer (SCLC) can express CXCR4 chemokine receptor, and inhibition potentially synergizes with… 
2014
2014
Abstract 4768: Novel peptidic CXCR4 antagonist LY2510924 disrupts the SDF-1α/CXCR4 axis resulting in anti-AML efficacyin vivo
Disruption of the SDF-1α/CXCR4 axis by CXCR4 inhibitors has been proven to be an attractive investigational therapeutic approach… 
2014
2014
Pronounced Anti-Leukemia Activity in Vivo of the Novel Peptidic CXCR4 Antagonist LY2510924 As a Single Agent and in Combination with Chemotherapy
LY2510924 is a novel selective peptidic CXCR4 antagonist that blocks SDF-1α from binding to its receptor. We have demonstrated… 
2013
2013
Abstract 1419: A phase I study of the CXCR4 peptide antagonist LY2510924 in patients with advanced cancer.
Background: The over-expression of C-X-C motif receptor 4 (CXCR4), a chemokine receptor implicated in tumor progression, tumor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)